Multiple myeloma embodies the paradigm of the deepest the response the longer the survival. However, there are conflicting results between the achievement of complete remission and MRD negativity, because some patients with persistent M-protein have nonetheless undetectable MRD. We reviewed the frequency of this discordancy and the outcome of these patients. We spotlighted possible explanations and consequences of conflicting response criteria, and suggest that MRD should be assessed in patients achieving very good partial response or better in clinical trials.
Subjects:
Lymphoid Neoplasia
This content is only available as a PDF.
Copyright © 2022 American Society of Hematology
2022
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal